Receptor screening technologies in the evaluation of Amazonian ethnomedicines with potential applications to cognitive deficits

Journal of Ethnopharmacology

Volumn 134, Issue 2, 2011, Pages 475-492

  McKenna, Dennis J ^a   Ruiz, Juan M ^b   Hoye, Thomas R ^c   Roth, Bryan L ^d   Shoemaker, Alan T ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSIDAD NACIONAL DE LA AMAZONÍA PERUANA   (Peru)

^c University of Minnesota   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e Gracia Ethnobotanicals   (Peru)

Author keywords

Cognitive disorders; Dementia; Drug prospecting; Ethnomedicine; Ethnopharmacology; Mental disorders; Radioligand assay; Schizophrenia

Indexed keywords

ADRENERGIC RECEPTOR; ALKALOID; FLAVONOID; INDOLE ALKALOID; ISOQUINOLINE ALKALOID; MUSCARINIC RECEPTOR; PLANT EXTRACT; SEROTONIN RECEPTOR; SESQUITERPENE; TRITERPENE;

ARTICLE; BINDING ASSAY; COGNITIVE DEFECT; DEMENTIA; DRUG SCREENING; ETHNOBOTANY; MEDICINAL PLANT; NONHUMAN; PERU; PHYTOCHEMISTRY; PSYCHOPHARMACOLOGY; RADIOASSAY; RADIORECEPTOR ASSAY; RECEPTOR BINDING; SCHIZOPHRENIA; TRADITIONAL MEDICINE;

COGNITION DISORDERS; DEMENTIA; DRUG DISCOVERY; ETHNOPHARMACOLOGY; HUMANS; INTERVIEWS AS TOPIC; MEDICINE, TRADITIONAL; NEUROTRANSMITTER AGENTS; PERU; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; PSYCHOTROPIC DRUGS; RECEPTORS, NEUROTRANSMITTER; SCHIZOPHRENIA;

EID: 79952680069     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2010.12.037     Document Type: Article

References (81)

1. Aguzzi, A., O'Connor, T., 2010. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nature Reviews. Drug Discovery 9, 237-248.
2. Andreasen, N.C., 1982. Negative symptoms in schizophrenia, definition and reliability. Archives of General Psychiatry 39, 784-788. (Pubitemid 12090301)
3. Armbruster, B.N., Roth, B.L., 2005. Mining the receptorome. Journal of Biological Chemistry 280, 5129-5132. (Pubitemid 40279980)
4. Ayala, F., 2003. Taxonomia Vegetal: Gymnospermae y Angiospermae de la Amazonía Peruana. Centro de Estudios Teológicos de la Amazonía (CETA), Iquitos, Peru.
5. Berger, M., Gray, J.A., Roth, B.L., 2009. The expanded biology of serotonin. Annual Review of Medicine 60, 355-366.
6. Bleuler, E., 1968. Dementia Praecox or the Group of Schizophrenias. International Universities Press, Madison, CT.
7. Creese, I., Burt, D.R., Snyder, S.H., 1976. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481-483.
8. Curzon, G., 1990. How reserpine and chlorpromazine act: the impact of key discoveries on the history of psychopharmacology. Trends in Pharmacological Sciences 11, 61-63. (Pubitemid 20041662)
9. Deahl, M., 1989. Betel nut-induced extrapyramidal syndrome: an unusual drug interaction. Movement Disorders 4, 330-332.
10. Dragunow, M., 2008. M3 muscarinic receptors as targets for drug development in neurodegenerative disorders. Nature Reviews. Drug Discovery 7, 1 p. following p. 185.
11. Duke, J.A., 1995. Commentary - novel psychotherapeutic drugs: a role for ethnobotany. Psychopharmacological Bulletin 31, 177-184.
12. Duke, J.A., Vasquez, R., 1994. Amazonian Ethnobotanical Dictionary. CRC Press, Boca Raton, FL.
13. Farlow, M.R., Evans, R.M., 1998. Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology 51 (Suppl. 1), S36-S44. (Pubitemid 28345340)
14. Farnsworth, N.R., 1993. Ethnopharmacology and future drug development: the North American experience. Journal of Ethnopharmacology 38, 145-152. (Pubitemid 23136059)
15. Fernandez, H.H., Friedman, J.H., 2003. Classification and treatment of tardive syndromes. Neurologist 9, 16-27. (Pubitemid 36164020)
16. Fugh-Berman, A., Cott, J.M., 1999. Dietary supplements and natural products as psychotherapeutic agents. Psychosomatic Medicine 61, 712-728. (Pubitemid 29455091)
17. Geyer, M.A., Vollenweider, F.X., 2008. Serotonin research: contributions to understanding psychoses. Trends in Pharmacological Sciences 29, 445-453.
18. Gray, J.A., Roth, B.L., 2007a. The pipeline and future of drug development in schizophrenia. Molecular Psychiatry 12, 904-922. (Pubitemid 47482704)
19. Gray, J.A., Roth, B.L., 2007b. Molecular targets for treating cognitive dysfunctions in schizophrenia. Schizophrenia Bulletin 33, 1100-1119. (Pubitemid 47347917)
20. Green, M., Kern, R., Heaton, R., 2005. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophrenia Research 72, 41-51.
21. Hanes, K.R., 2001. Antidepressant effects of the herb Salvia divinorum: a case report. Journal of Clinical Psychopharmacology 21, 634-635. (Pubitemid 33116675)
22. Hedlund, P.B., 2009. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berlin) 206, 345-354.
23. Hill, S.K., Bishop, J.R., Palumbo, D., Sweeney, J.A., 2010. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Review of Neurotherapeutics 10, 43-57.
24. Hodder, P., Mull, R., Cassaday, J., Berry, K., Strulovici, B., 2004. Miniaturization of intracellular calcium functional assays to 1536-well plate format using a fluorometric imaging plate reader. Journal of Biomolecular Screening 9, 417-426.
25. Howes, M.J., Perry, N.S., Houghton, P.J., 2003. Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytotherapy Research 17, 1-18. (Pubitemid 36205453)
26. Hu, G.C., 1984. Anticonvulsants used for controlling induced seizures during the treatment of schizophrenia with lactoni Coriariae. Zhong Xi Yi Jie He Za Zhi 4, 675-678, 644.
27. Jäger, A.K., Mohoto, S.P., van Heerden, F.R., Viljoen, A.M., 2004. Activity of a traditional South African epilepsy remedy in the GABA-benzodiazepine receptor assay. Journal of Ethnopharmacology 96, 603-606.
28. Kegeles, L.S., Abi-Dargham, A., Frankle, W.G., Gil, R., Cooper, T.B., Slifstein, M., Hwang, D.R., Huang, Y., Haber, S.N., Laruelle, M., 2010. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Archives of General Psychiatry 67, 231-239.
29. Keiser, M.J., Setola, V., Irwin, J.J., Laggner, C., Abbas, A.I., Hufeisen, S.J., Jensen, N.H., Kuijer, M.B., Matos, R.C., Tran, T.B., Whaley, R., Glennon, R.A., Hert, J., Thomas, K.L., Edwards, D.D., Shoichet, B.K., Roth, B.L., 2009. Predicting new molecular targets for known drugs. Nature 462, 175-181.
30. 2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biological Psychiatry 65, 1024-1031.
31. Kidd, P.M., 1999.Areview of nutrients and botanicals in the integrative management of cognitive dysfunction. Alternative Medicine Review 4, 144-161. (Pubitemid 29316278)
32. Kirby, M., Lawlor, B.A., 1995. Biologic markers and neurochemical correlates of agitation and psychosis in dementia. Journal of Geriatric Psychiatry and Neurology 8 (Suppl. 1), S2-7.
33. Kirkpatrick, B., Fenton, W.S., Carpenter Jr., W.T., Marder, S.R., 2006. The NIMH-MATRICS consensus statement on negative symptoms. Schizophrenia Bulletin 32, 214-219.
34. Lake, J., 2000. Psychotropic medications from natural products: A review of promising research and recommendations. Alternative Therapies in Health and Medicine 6, 36-60. (Pubitemid 30441325)
35. Lal, S., Iskandar, H., 2000. St. John's wort and schizophrenia. Canadian Medical Association Journal 163, 262-263.
36. Lawrence, A.D., Sahakian, B.J., 1998. The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems. Neurochemical Research 23, 787-794. (Pubitemid 28173586)
37. Logan, M.H., 1993. New lines of inquiry on the illness of susto. Medical Anthropology 15, 189-200.
38. Loub, W.D., Farnsworth, N.R., Soejarto, D.D., Quinn, M.L., 1985. NAPRALERT, computer handling of natural product research data. Journal of Chemical Information and Computer Sciences 25, 99-103.
39. Lysaker, P.H, Buck, K.D., 2007. Neurocognitive deficits as a barrier to psychosocial function in schizophrenia: effects on learning, coping, and self-concept. Journal of Psychosocial Nursing and Mental Health Services 45, 24-30.
40. Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., Kivipelto, M., 2010. Alzheimer's disease: clinical trials and drug development. Lancet Neurology 9, 702-716.
41. Marder, S.R., Ames, D., Wirshing, W.C., Van Putten, T., 1993. Schizophrenia. The Psychiatric Clinics of North America 16, 567-587. (Pubitemid 23274046)
42. McKenna, D.J., Towers, G.H.N., Abbott, F.S., 1984. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of Ayahuasca. Journal of Ethnopharmacology 10, 195-223. (Pubitemid 14081500)
43. McKenna, D.J., Towers, G.H.N., Luna, L.E., 1995. Biodynamic constituents in Ayahuasca admixture plants: an uninvestigated folk pharmacopoeia. In: von Reis, S., Schultes, R.E. (Eds.), Ethnobotany: Evolution of a Discipline. Dioscorides Press, Portland, OR, pp. 349-361.
44. Meltzer, C.C., Smith, G., DeKosky, S.T., Pollock, B.G., Mathis, C.A., Moore, R.Y., Kupfer, D.J., Reynolds 3rd, C.F., 1998. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 18, 407-413.
45. Meltzer, H.Y., Park, S., Kessler, R., 1991. Cognition, schizophrenia, and the atypical antipsychotic drugs. Proceedings of the National Academy of Sciences of the United States of America 96, 13591-13593.
46. Misra, R., 1998. Modern drug development from traditional medicinal plants using radioligand receptor-binding assays. Medicinal Research Reviews 18, 383-402. (Pubitemid 28507068)
47. Nichols, D.E., 2004. Hallucinogens. Pharmacology and Therapeutics 101, 131-181. (Pubitemid 38167565)
48. Nielsen, N.D., Sandager, M., Stafford, G.I., van Staden, J., Jäger, A.K., 2004. Screening of indigenous plants from South Africa for affinity to the serotonin reuptake transport protein. Journal of Ethnopharmacology 94, 159-166.
49. Ott, B.R., Owens, N.J., 1998. Complementary and alternative medicines for Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology 11, 163-173. (Pubitemid 29178742)
50. Parker, V., Wong, A.H., Boon, H.S., Seeman, M.V., 2001. Adverse reactions to St John's Wort. Canadian Journal of Psychiatry 46, 77-79. (Pubitemid 32209349)
51. Pert, C.B., Snyder, S.H., 1973. Opiate receptor: demonstration in nervous tissue. Science 179, 1011-1014.
52. Peuskens, J., Demily, C., Thibaut, F., 2005. Treatment of cognitive dysfunction in schizophrenia. Clinical Therapeutics 27 (Suppl. A), S25-S37. (Pubitemid 41356721)
53. Phillipson, J.D., 1999. Radioligand-receptor binding assays in the search for bioactive principles from plants. The Journal of Pharmacy and Pharmacology 51, 493-503. (Pubitemid 29319773)
54. Prouteau, A., Verdoux, H., Briand, C., Lesage, A., Lalonde, P., Nicole, L., Reinharz, D., Stip, E., 2005. Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. Schizophrenia Research 77, 343-353. (Pubitemid 41112227)
55. Ropper, A.H., Brown, R.H. (Eds.), 2005. Adams and Victor's Principles of Neurology. , 8th edition. McGraw Hill, New York, NY.
56. Roth, B.L., Baner, K., Westkaemper, R., Siebert, D., Rice, K.C., Steinberg, S., Ernsberger, P., Rothman, R.B., 2002. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences of the United States of America 99, 11934-11939. (Pubitemid 34994502)
57. Roth, B.L., Hanizavareh, S.M., Blum, A.E., 2004b. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berlin) 174, 17-24. (Pubitemid 38925086)
58. Roth, B.L., Lopez, E., Patel, S., Kroeze, W., 2000. Multiplicity of serotonin receptors: useless diverse molecules or an embarrassment of riches? The Neuroscientist 6, 252-262.
59. Roth, B.L., Sheffler, D.J., Kroeze, W.K., 2004a. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Reviews. Drug Discovery 3, 353-359. (Pubitemid 38499762)
60. Russo, E.B., 1992. Headache treatments by native peoples of the Ecuadorian Amazon: a preliminary cross-disciplinary assessment. Journal of Ethnopharmacology 36, 193-206.
61. Sampson, J.H., Phillipson, J.D., Bowery, N.G., O'Neill, M.J., Houston, J.G., Lewis, J.A., 2000. Ethnomedicinally selected plants as sources of potential analgesic compounds: indication of in vitro biological activity in receptor binding assays. Phytotherapy Research 14, 24-29. (Pubitemid 30087946)
62. Schotte, A., Janssen, P.F., Gommeren, W., Luyten, W.H., Van Gompel, P., Lesage, A.S., De Loore, K., Leysen, J.E., 1996. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berlin) 124, 57-73. (Pubitemid 26112775)
63. Schultes, R.E., 1981. Phytochemical gaps in our knowledge of hallucinogens. In: Reinhold, L., Harbourne, J.B., Swain, T. (Eds.), Progress in Phytochemistry, vol. 7. Pergamon Press, Oxford, UK, pp. 301-331.
64. Schultes, R.E., 1993. Plants in treating senile dementia in the northwest Amazon. Journal of Ethnopharmacology 38, 129-135. (Pubitemid 23136057)
65. Schultes, R.E., 1994. Amazonian ethnobotany and the search for new drugs. Ciba Foundation Symposium 185, 106-112.
66. Schultes, R.E., Raffauff, R., 1990. The Healing Forest: Medicinal and Toxic Plants of the Northwest Amazon. Timber Press, Portland, OR.
67. Shapiro, D.A., Renock, S., Arrington, E., Chiodo, L.A., Liu, L.X., Sibley, D.R., Roth, B.L., Mailman, R., 2003. Aripiprazole, a novel atypical antipsychotic drug with a unique androbust pharmacology. Neuropsychopharmacology 28, 1400-1411. (Pubitemid 41070874)
68. Sullivan, R.J., Allen, J.S., Otto, C., Tiobech, J., Nero, K., 2000. Effects of chewing betel nut (Areca catechu) on the symptoms of people with schizophrenia in Palau, Micronesia. Britsh Journal of Psychiatry 177, 174-178. (Pubitemid 30624831)
69. Van Beek, T.A., Verpoorte, R., Svendsen, A.B., Leeuwenberg, A.J., Bisset, N.G., 1984. Tabernaemontana L. (Apocynaceae): a review of its taxonomy, phytochemistry, ethnobotany and pharmacology. Journal of Ethnopharmacology 10, 1-156. (Pubitemid 14171715)
70. Velligan, D.I., Mahurin, R.K., Diamond, P.L., Hazleton, B.C., Eckert, S.L., Miller, A.L., 1997. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophrenia Research 25, 21-31. (Pubitemid 27239627)
71. Von Reis, S., 1973. Drugs and Foods from Little Known Plants: Notes in Harvard University Herbaria. Harvard University Press, Cambridge, MA.
72. Von Reis, S., Lipp, F.J., 1982. New Plant Sources for Drugs and Foods from the New York Botanical Garden Herbarium. Harvard University Press, Cambridge, MA.
73. Vortherms, T.A., Roth, B.L., 2006. Salvinorin A: from natural product to human therapeutics. Molecular Interventions 6, 257-265. (Pubitemid 44556046)
74. Wang, B., 1986. Observations on the effects of traditional Chinese medicine to invigorate blood and relieve stasis in treating schizophrenia. Zhonghua Shen Jing Jing Shen Ke Za Zhi 19, 44-46.
75. Wilson, L.G., 1979. Cross-cultural differences in indicators of improvement from psychosis: the case of betel nut chewing. The Journal of Nervous and Mental Disease 167, 250-251. (Pubitemid 9167958)
76. Winterer, G., Weinberger, D.R., 2004. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends in Neurosciences 27, 683-690. (Pubitemid 39335839)
77. Yamada, K., Kanba, S., Yagi, G., Asai, M., 1997. Effectiveness of herbal medicine (shakuyaku-kanzo-to) for neuroleptic-induced hyperprolactinemia. Journal of Clinical Psychopharmacology 17, 234-235. (Pubitemid 27261788)
78. Yuan, D.J., 1979. Clinical observations on the effects of Lactoni Coriariae and Tutin in the treatment of schizophrenia (report of 140 cases) (author's transl). Zhonghua Shen Jing Jing Shen Ke Za Zhi 12, 196-200.
79. Zhang, L.D., Tang, Y.H., Zhu, W.B., Xu, S.H., 1987. Comparative study of schizophrenia treatment with electroacupuncture, herbs and chlorpromazine. Chinese Medical Journal (England) 100, 152-157.
80. Zhang, X.Y., Zhou, D.F., Su, J.M., Zhang, P.Y., 2001. The effect of extract of Ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. Journal of Clinical Psychopharmacology 21, 85-88. (Pubitemid 32096755)
81. Zhu, M., Bowery, N.G., Greengrass, P.M., Phillipson, J.D., 1996. Applications of radio-ligand receptor binding assays in the search for CNS active principles from Chinese medicinal plants. Journal of Ethnopharmacology 54, 153-164. (Pubitemid 26393481)